Home Newsfeeds JP Morgan Initiates Coverage On Senti Biosciences with Neutral Rating

JP Morgan Initiates Coverage On Senti Biosciences with Neutral Rating

JP Morgan analyst Brian Cheng initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Neutral rating.

byBenzinga Newsdesk

December 16, 2022

1 minute read

JP Morgan analyst Brian Cheng initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Neutral rating.

Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $30

By Benzinga Newsdesk

September 14, 7:31 AM

Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $26 to $30.

AKRO

Wells Fargo Maintains Equal-Weight on Magna International, Lowers Price Target to $60

By Benzinga Newsdesk

December 21, 8:32 AM

Wells Fargo analyst Colin Langan maintains Magna International (NYSE:MGA) with a Equal-Weight and lowers the price target from $62 to $60.

MGA

4 Walmart Analysts Raise Price Targets After Q2 Earnings Beat: ‘Leader And Market Share Gainer’

By Wayne Duggan

August 17, 3:27 PM

Walmart Inc (NYSE: WMT) shares traded higher Wednesday after the discount retailer reported impressive second-quarter earnings growth and reiterated its full-year guidance.

WMT

Tapestry Likely To Report Higher Q1 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

By Lisa Levin

November 9, 3:51 AM

Tapestry, Inc. (NYSE: TPR) is projected to release financial results for its fiscal 2024 first quarter, before the opening bell on Nov. 9, 2023.

TPR

JP Morgan Initiates Coverage On Senti Biosciences with Neutral Rating

Related Posts

Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $30

Wells Fargo Maintains Equal-Weight on Magna International, Lowers Price Target to $60

4 Walmart Analysts Raise Price Targets After Q2 Earnings Beat: ‘Leader And Market Share Gainer’

Tapestry Likely To Report Higher Q1 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts